Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer stem cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    344 result(s) found for: Cancer stem cells. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003856-19 Sponsor Protocol Number: CVB2018-2 Start Date*: 2019-01-09
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK
    Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients
    Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-005186-31 Sponsor Protocol Number: 01062017 Start Date*: 2018-06-06
    Sponsor Name:Department of Plastic Surgery, Breast and Burns Treatment
    Full Title: Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy
    Medical condition: This study will include patients with genetic predisposition to development of breast cancer, who are offered prophylactic bilateral skin-sparring mastectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10071981 BRCA2 gene mutation PT
    20.0 10018065 - General disorders and administration site conditions 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003362-84 Sponsor Protocol Number: FSJD-DIPG-DC Start Date*: 2016-05-18
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG )
    Medical condition: Diffuse intrinsic pontine glioma (DIPG)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002210-36 Sponsor Protocol Number: PR2006-03 Start Date*: 2006-11-10
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC)
    Medical condition: Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004298-41 Sponsor Protocol Number: Pancreathipec1.0. Start Date*: 2017-05-25
    Sponsor Name:Hospital General Ciudad Real
    Full Title: Intrabdominal hyperthermic chemotherapy using gemcitabine to treat pancreatic carcinomatosis
    Medical condition: A population of malignant transformation stem cells, called tumor stem cells, extremely resistant to chemotherapeutic drugs, has been identified as the origin of pancreatic cancer. In our study, we...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002383-13 Sponsor Protocol Number: Cord_Blood_Expansion_(SR-1) Start Date*: 2016-10-18
    Sponsor Name:Erasmus MC
    Full Title: Umbilical cord blood transplantation in high-risk hematological patients using stemregenin-1 expanded hematopoietic stem cells. A feasibility study focussing on engraftment and hematopoietic recov...
    Medical condition: Patients with high-risk hematological diseases, who need a allogeneic stem cell transplantation but who lack a matched unrelated donor
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061187 Haematopoietic neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018467-42 Sponsor Protocol Number: VidazaAlloStudy Start Date*: 2011-05-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability
    Medical condition: Myelodysplastic Syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004928-21 Sponsor Protocol Number: Auto-Allo-TSCTinMM Start Date*: 2008-06-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study
    Medical condition: Multiple Myeloma Stage II or III according to Salmon and Durie
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004125-23 Sponsor Protocol Number: CCRG19-002 Start Date*: 2021-05-10
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma
    Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002879-34 Sponsor Protocol Number: PSCT16 Start Date*: 2013-03-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation
    Medical condition: Patients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023436-16 Sponsor Protocol Number: HOVON 107 Start Date*: 2011-05-31
    Sponsor Name:HOVON Foundation
    Full Title: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.
    Medical condition: stem cell mobilization
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053948 Hematopoietic stem cell mobilization LLT
    12.1 10024329 Leukemia LLT
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Restarted)
    Trial results: View results
    EudraCT Number: 2021-001005-67 Sponsor Protocol Number: AlloRelapseMMStudy Start Date*: 2022-05-11
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004517-34 Sponsor Protocol Number: AMLSCT-BFM2007 Start Date*: 2010-01-13
    Sponsor Name:Hannover Medical School
    Full Title: Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML Multi Center Therapy Concept
    Medical condition: Relapsed or refractory Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001051-39 Sponsor Protocol Number: FMG-MM-02 Start Date*: 2012-11-15
    Sponsor Name:Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine
    Full Title: A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide ma...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003809-22 Sponsor Protocol Number: MDS Start Date*: 2022-09-09
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syn...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000351-14 Sponsor Protocol Number: PR201206 Start Date*: 2012-10-24
    Sponsor Name:Barts Health NHS Trust
    Full Title: A PHASE II STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT) OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: castration resistant prostate cancer patients
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002198-40 Sponsor Protocol Number: DEN-STEM Start Date*: 2018-01-26
    Sponsor Name:Oslo University Hospital
    Full Title: Open label randomized phase II/III trial of dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM)
    Medical condition: Glioblastoma brain tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003528-19 Sponsor Protocol Number: Start Date*: 2013-04-16
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
    Full Title: STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION
    Medical condition: pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:57:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA